BUSINESS
Mental Health Series Part 2: At up to Rs 19,000 for therapy, how many in India can afford treatment?
Amidst a renewed focus on mental health issues after actor Sushant Singh Rajput’s death by suicide, it is a reality that treatment for anxiety, depression and allied issues is unaffordable in India.
BUSINESS
Mental health series Part-1 | Sushant Singh Rajput’s death: Depression and role of COVID-19 in increasing psychological problems
Suicide is an extreme manifestation of mental health problem and is considered as a grey area medically. Even psychiatrists find it difficult to identify a suicidal person beforehand.
WORLD
Coronavirus pandemic | USFDA revokes emergency use status of hydroxychloroquine drug touted by Trump for COVID-19
US FDA revoked the authorization following a request from Gary Disbrow, acting director of the Biomedical Advanced Research and Development Authority (BARDA).
BUSINESS
Expect COVID-19 vaccine to enter phase-1 human trial by October: Panacea Biotec's Rajesh Jain
Panacea Biotec said the aim is to manufacture over 500 million doses of COVID-19 candidate vaccine, with over 40 million doses expected to be available for delivery early next year.
BUSINESS
CDSCO reviewing Remdesivir applications on priority basis
"Being an injectable formulation, testing for assay, identity, impurities, bacterial endotoxin test and sterility become very critical for patient safety and this data need to be provided by the companies," it added.
BUSINESS
COVID-19 treatment | Check advisory from Ministry of Health and Family Welfare
The health ministry has provided protocol on use of Remdesivir, Convalescent plasma, Toclizumab, and Hydroxychloroquine.
BUSINESS
Why wait for Gilead's antiviral Remdesivir may not end soon
Indian drug regulator has been reviewing the marketing authorisation applications of Remdesivir of four Indian companies: Cipla, Hetero, Jubilant Life Sciences and BDR Pharmaceuticals
BUSINESS
US approves Biocon-Mylan's version of insulin glargine, companies working on interchangeability
Biocon-Mylan's Semglee is identical to Sanofi’s Lantus and is approved for the same indications.
BUSINESS
GSK is world's largest vaccine maker. Yet it has been tame with its COVID-19 strategy
GSK is betting on its adjuvant technology to support companies developing COVID-19 vaccines.
BUSINESS
Panacea joins hands with Ireland's Refana to develop COVID-19 vaccine by early next year
Panacea Biotec Managing Director Rajesh Jain has said the aim is to manufacture over 500 million doses of COVID-19 candidate vaccine, with over 40 million doses expected to be available for delivery early next year.
BUSINESS
EXCLUSIVE: Bangladesh drugmakers signed up by Maharashtra govt don't have licence to sell remdesivir in India
CDSCO hasn't received application from any Bangladesh companies for remdesivir import licence.
BUSINESS
A Bangladesh pharma company causes heartburn in India's drugmakers
Eskayef Pharma had been quick to take advantage of international trade rules that allow nations defined by the United Nations as least-developed countries to ignore patents and produce affordable drugs.
BUSINESS
Healthtech startup HealthPlix raises $6 million from JSW Ventures, others
The startup enabled more than 5,000 doctors in digitising their entire clinical operations and clinical treatment methodologies
BUSINESS
Debate on Hydroxychloroquine’s efficacy: Why we need to be careful about research papers
The retraction of the Lancet study and the restart of HCQ trial by WHO do not mean that the debate on HCQ's efficacy is settled
BUSINESS
L&T facing labour squeeze at project sites, banking on Gulf returned workers
Subrahmanyan says they need at least 100,000 workers to ensure the work goes on full throttle.
BUSINESS
How Serum Institute became the Jio of coronavirus vaccine deals
AstraZeneca is the latest deal that Pune-based Serum Institute has stitched together. How did the 50-year-old vaccine maker become the face of the Indian fight against COVID-19?
BUSINESS
ICMR validates three IgG Elisa test kits to be used in sero-survey
The IgG Elisa test kit helps in detecting immunoglobulin class G antibody in the blood samples and determine who had previously been infected with COVID-19 and may have developed an immunity.
BUSINESS
Explainer: Here is what led to WHO's flip-flop on HCQ clinical trial
Many scientists have termed the WHO decision to suspend the trial HCQ study as a knee -jerk reaction.
BUSINESS
Online doctor consulting platform DocsApp raises $20 million, announces merger with Medibuddy
DocsApp announced merger with cashless digital healthcare platform Medibuddy for an undisclosed amount.
BUSINESS
COVID-19 crisis | HCQ, other medicines and tests now available for sale on dark web marketplaces
For instance Empire Market—one of the most popular places to buy illegal goods on the dark web and a prominent dark web market—has 49 listings for chloroquine and hydroxychloroquine.
BUSINESS
Bharat Biotech secures funding from CEPI for developing Chikungunya vaccine
Bharat Biotech's BBV87 vaccine is an inactivated whole virion vaccine based on a strain derived from an East, Central, South African (ECSA) genotype.
BUSINESS
Only 30% of COVID-19 testing capacity utilised, says diagnostic chain Metropolis Healthcare
Shah denied that cost has anything to do with the reluctance of government to utilise the testing capacity with private labs.
BUSINESS
Gilead gets conditional approval from India regulator to market remdesivir for COVID-19
The conditional marketing authorisation for remdesivir was granted under the accelerated review process considering the emergency situation and unmet medical needs
BUSINESS
Itolizumab, Biocon's drug with Cuban link, in hunt for COVID-19 breakthrough
It has been found that 'cytoskine storm' is the leading cause of deaths of COVID-19. Cytokines stimulate immune system to kill virus. But in COVID-19, the virus tricks our body to produce uncontrollable flood of cytokines, which while helping in fighting virus, also worsens a patient's condition.
